Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin

Tanya Jindal, Li Zhang, Prianka Deshmukh, Kevin Reyes, Emily Chan, Vipul Kumar, Xiaolin Zhu, Edward Maldonado, Stephanie Feng, Michelle S. Johnson, Austin Angelidakis, Daniel H. Kwon, Arpita Desai, Hala T. Borno, Rohit Bose, Anthony Wong, Julian C. Hong, Peter R. Carroll, Maxwell V. Meng, Sima P. Porten, Rahul Aggarwal, Eric J. Small, Lawrence Fong, Jonathan Chou, Terence W. Friedlander, Ivan de Kouchkovsky, Vadim S. KoshkinClinical 2023 · DOI

Abstract

In this single-center retrospective analysis, patients with UCS had a distinct somatic genomic profile relative to patients with pUC. Patients with UCS also had inferior outcomes to ICIs and EV compared to patients with pUC.
BibTeX
@inproceedings{jindal2023impact,
  author = {Tanya Jindal and Li Zhang and Prianka Deshmukh and Kevin Reyes and Emily Chan and Vipul Kumar and Xiaolin Zhu and Edward Maldonado and Stephanie Feng and Michelle S. Johnson and Austin Angelidakis and Daniel H. Kwon and Arpita Desai and Hala T. Borno and Rohit Bose and Anthony Wong and Julian C. Hong and Peter R. Carroll and Maxwell V. Meng and Sima P. Porten and Rahul Aggarwal and Eric J. Small and Lawrence Fong and Jonathan Chou and Terence W. Friedlander and Ivan de Kouchkovsky and Vadim S. Koshkin},
  title = {{Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1016/j.clgc.2023.05.007},
}

Loading related content...

Figure